IL224237A - Pharmaceutical preparation containing a classical oligonucleotide complex - Google Patents

Pharmaceutical preparation containing a classical oligonucleotide complex

Info

Publication number
IL224237A
IL224237A IL224237A IL22423713A IL224237A IL 224237 A IL224237 A IL 224237A IL 224237 A IL224237 A IL 224237A IL 22423713 A IL22423713 A IL 22423713A IL 224237 A IL224237 A IL 224237A
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
chelate complexes
oligonucleotide chelate
oligonucleotide
complexes
Prior art date
Application number
IL224237A
Other languages
English (en)
Hebrew (he)
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45594559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL224237(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of IL224237A publication Critical patent/IL224237A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
IL224237A 2010-08-20 2013-01-15 Pharmaceutical preparation containing a classical oligonucleotide complex IL224237A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37525710P 2010-08-20 2010-08-20
PCT/CA2011/000956 WO2012021985A1 (en) 2010-08-20 2011-08-18 Oligonucleotide chelate complexes

Publications (1)

Publication Number Publication Date
IL224237A true IL224237A (en) 2015-09-24

Family

ID=45594559

Family Applications (1)

Application Number Title Priority Date Filing Date
IL224237A IL224237A (en) 2010-08-20 2013-01-15 Pharmaceutical preparation containing a classical oligonucleotide complex

Country Status (35)

Country Link
US (2) US8513211B2 (cg-RX-API-DMAC10.html)
EP (1) EP2605794B1 (cg-RX-API-DMAC10.html)
JP (1) JP5775581B2 (cg-RX-API-DMAC10.html)
KR (3) KR20150039873A (cg-RX-API-DMAC10.html)
CN (2) CN103768086B (cg-RX-API-DMAC10.html)
AU (1) AU2011291401B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013003875B1 (cg-RX-API-DMAC10.html)
CA (2) CA2855690C (cg-RX-API-DMAC10.html)
CL (1) CL2013000445A1 (cg-RX-API-DMAC10.html)
CO (1) CO6670525A2 (cg-RX-API-DMAC10.html)
CR (1) CR20130069A (cg-RX-API-DMAC10.html)
CU (1) CU20130022A7 (cg-RX-API-DMAC10.html)
CY (1) CY1118207T1 (cg-RX-API-DMAC10.html)
DK (1) DK2605794T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2013000041A (cg-RX-API-DMAC10.html)
EA (1) EA026660B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP13012449A (cg-RX-API-DMAC10.html)
ES (1) ES2598556T3 (cg-RX-API-DMAC10.html)
GT (1) GT201300040A (cg-RX-API-DMAC10.html)
HR (1) HRP20161333T1 (cg-RX-API-DMAC10.html)
HU (1) HUE029521T2 (cg-RX-API-DMAC10.html)
IL (1) IL224237A (cg-RX-API-DMAC10.html)
LT (1) LT2605794T (cg-RX-API-DMAC10.html)
MX (1) MX340294B (cg-RX-API-DMAC10.html)
MY (1) MY160961A (cg-RX-API-DMAC10.html)
NZ (1) NZ606364A (cg-RX-API-DMAC10.html)
PH (1) PH12013500192B1 (cg-RX-API-DMAC10.html)
PL (1) PL2605794T3 (cg-RX-API-DMAC10.html)
PT (1) PT2605794T (cg-RX-API-DMAC10.html)
RS (1) RS55245B1 (cg-RX-API-DMAC10.html)
SG (1) SG187165A1 (cg-RX-API-DMAC10.html)
SI (1) SI2605794T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201600370B (cg-RX-API-DMAC10.html)
WO (1) WO2012021985A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201300497B (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6047270B2 (ja) 2006-08-11 2016-12-21 バイオマリン テクノロジーズ ベー.フェー. Dnaリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
JP5646320B2 (ja) 2007-05-11 2014-12-24 アダイニクス, インコーポレイテッド 遺伝子発現と疼痛
NZ584793A (en) 2007-10-26 2012-05-25 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
CA2862628C (en) 2012-01-27 2021-08-24 Prosensa Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
PT2841578T (pt) 2012-04-23 2017-08-10 Biomarin Tech Bv Resumo
RU2668136C2 (ru) * 2012-05-10 2018-09-26 Эйдинкс, Инк. Композиции для доставки активных ингредиентов
HUE054875T2 (hu) * 2012-05-18 2021-10-28 Replicor Inc Oligonukleotid kelátkomplex-polipeptid készítmények és eljárások
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
CN104603271B (zh) * 2012-07-03 2019-07-19 马林生物科技有限公司 用于治疗肌肉萎缩症患者的寡核苷酸
CN104837501B (zh) 2012-08-30 2018-11-02 里普利科股份有限公司 治疗乙型肝炎及丁型肝炎感染的方法
KR20170029577A (ko) 2014-07-10 2017-03-15 레플리코르 인코포레이티드 B형 간염 및 d형 간염 바이러스 감염의 치료 방법
CN106661578B (zh) 2014-08-15 2020-08-04 埃迪恩克斯股份有限公司 用于疼痛治疗的寡核苷酸诱饵
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
JP2018513127A (ja) 2015-04-23 2018-05-24 ジェロン・コーポレーションGeron Corporation 多価カチオン塩組成物を用いたポリヌクレオチド調製方法
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20200147124A1 (en) * 2018-11-08 2020-05-14 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20230250125A1 (en) 2020-04-01 2023-08-10 Janssen Biopharma, Inc. Nucleic acid polymers
WO2022109129A1 (en) * 2020-11-20 2022-05-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
JP2024521897A (ja) * 2021-06-02 2024-06-04 アタランタ セラピューティクス,インコーポレーテッド 治療用オリゴヌクレオチドを中枢神経系に送達するための組成物及び方法
CN117616121A (zh) 2021-07-09 2024-02-27 葛兰素史密斯克莱知识产权(第3号)有限公司 寡核苷酸用于具有肾脏损伤的个体的用途
EP4728073A1 (en) * 2023-06-16 2026-04-22 Ractigen Therapeutics Oligonucleotide formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2300938A1 (en) * 1997-08-20 1999-02-25 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
JP3667047B2 (ja) * 1997-09-12 2005-07-06 キヤノン株式会社 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
US6653467B1 (en) * 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
JP4836366B2 (ja) * 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
WO2005023829A1 (ja) * 2003-09-02 2005-03-17 Japan Science And Technology Agency 金属錯体型核酸
WO2005026188A1 (ja) * 2003-09-08 2005-03-24 Japan Science And Technology Agency 金属錯体型核酸
WO2007005626A1 (en) * 2005-07-01 2007-01-11 Bioveris Corporation Compositions and methods for detecting, amplifying, and/or isolating nucleic acids
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents

Also Published As

Publication number Publication date
MX2013001668A (es) 2013-07-22
HUE029521T2 (en) 2017-03-28
KR101606495B1 (ko) 2016-03-28
JP2013536195A (ja) 2013-09-19
CL2013000445A1 (es) 2013-11-22
ES2598556T3 (es) 2017-01-27
CA2806616A1 (en) 2012-02-23
JP5775581B2 (ja) 2015-09-09
ZA201300497B (en) 2013-09-25
EA201300259A1 (ru) 2013-12-30
US8513211B2 (en) 2013-08-20
EA026660B1 (ru) 2017-05-31
SMT201600370B (it) 2016-11-10
BR112013003875B1 (pt) 2021-10-05
US8716259B2 (en) 2014-05-06
AU2011291401A1 (en) 2013-01-10
HRP20161333T1 (hr) 2016-12-02
CN103052405A (zh) 2013-04-17
EP2605794B1 (en) 2016-07-20
RS55245B1 (sr) 2017-02-28
PL2605794T3 (pl) 2017-01-31
KR20150082685A (ko) 2015-07-15
CR20130069A (es) 2013-09-20
US20130296410A1 (en) 2013-11-07
KR20150039873A (ko) 2015-04-13
US20120046348A1 (en) 2012-02-23
SG187165A1 (en) 2013-02-28
HK1184058A1 (zh) 2014-01-17
PH12013500192B1 (en) 2018-11-23
MX340294B (es) 2016-07-04
CU20130022A7 (es) 2013-04-19
MY160961A (en) 2017-03-31
CA2855690A1 (en) 2012-02-23
KR20130099067A (ko) 2013-09-05
CA2855690C (en) 2015-08-25
PH12013500192A1 (cg-RX-API-DMAC10.html) 2013-03-11
AU2011291401B2 (en) 2014-11-27
WO2012021985A1 (en) 2012-02-23
CA2806616C (en) 2015-08-11
ECSP13012449A (es) 2013-04-30
LT2605794T (lt) 2016-10-25
GT201300040A (es) 2014-09-02
HK1198123A1 (en) 2015-03-13
CN103052405B (zh) 2015-11-25
PT2605794T (pt) 2016-10-25
DOP2013000041A (es) 2017-12-15
NZ606364A (en) 2014-12-24
DK2605794T3 (en) 2016-10-24
EP2605794A4 (en) 2014-07-02
CO6670525A2 (es) 2013-05-15
BR112013003875A2 (en) 2018-03-13
CY1118207T1 (el) 2017-06-28
CN103768086A (zh) 2014-05-07
EP2605794A1 (en) 2013-06-26
SI2605794T1 (sl) 2017-01-31
CN103768086B (zh) 2015-10-14

Similar Documents

Publication Publication Date Title
ZA201300497B (en) Oligonucleotide chelate complexes
ZA201300458B (en) C-met-modulator pharmaceutical compositions
ZA201301766B (en) Pharmaceutical compositions
IL223535A (en) Solid medicinal compositions
IL245326B (en) pharmaceutical preparation
ZA201207670B (en) Pharmaceutical compositions
IL221416A0 (en) Alpha-emititng complexes
ZA201300718B (en) Pharmaceutical compositions
LT2619182T (lt) Farmacinė kompozicija
IL225457A0 (en) Pharmaceutical composition
PT2585216T (pt) Complexos de п-alilpaládio e п-alilníquel para utilização como catalisadores em reações de acoplamento de carbono-carbono e carbono-azoto
ZA201303223B (en) Pharmaceutical compositions
GB201010453D0 (en) Pharmaceutical composition
IL221385A0 (en) Nucleic acid complexes
IL226554A (en) Medicinal preparations containing alisporiovir
SG10201508982TA (en) Pharmaceutical compositions
IL221501A (en) Medicinal product containing miramistine
EP2560678A4 (en) PHARMACEUTICAL COMPOSITIONS
SI2672985T1 (sl) Farmacevtski sestavki, brez citrata, ki obsegajo anakinro
GB201007290D0 (en) Pharmaceutical powder compositions
GB201001911D0 (en) Pharmaceutical composition
ZA201303732B (en) Pharmaceutical compositions
GB201008590D0 (en) Pharmaceutical compositions
GB201005403D0 (en) Novel pharmaceutical compositions
HU1000006D0 (en) Improved pharmaceutical composition

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed